Class / Patent application number | Description | Number of patent applications / Date published |
514392000 | Divalent chalcogen or acyclic nitrogen double bonded at 2-position, or tautomeric equivalent | 48 |
20080221186 | 4-(substituted cycloalkylmethyl) Imidazole-2-Thiones, 4-(substituted cycloalkenylmethyl) Imidazole-2-Thiones, 4-(substituted cycloalkylmethyl) Imidazol-2-Ones and 4-(substituted cycloalkenylmethyl) Imidazole-2-Ones and related compounds - Compounds of Formula 1 | 09-11-2008 |
20080255218 | Melanin-Concentrating Hormone Receptor Antagonists and Methods of Use - This invention relates generally to N-benzylamino cyclic thioureas, pharmaceutical compositions containing them, and their use as antagonists of melanin-concentrating hormone receptor (MCH receptor). | 10-16-2008 |
20090048320 | AMINO-5-[4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS FOR THE INHIBITION OF BETA-SECRETASE - The present invention provides compounds and methods for the use thereof to inhibit β-secretase (BACE) and treat β-amyloid deposits and neurofibrillary tangles. | 02-19-2009 |
20090149523 | USE OF N-AMINOIMIDAZOLE CYTOPROTECTIVE COMPOUNDS FOR TREATING CELL DEATH AND/OR GSK-3 MEDIATED DISEASES - The present invention relates to the use of N-aminoimidazole or N-aminoimidazole-thione derivatives as cytoprotective compounds in vitro and in vivo and for the treatment or prevention of cell death mediated disorders and/or GSK-3 mediated disorders or processes. | 06-11-2009 |
20090192206 | MERCAPTOIMIDAZOLES AS CCR2 RECEPTOR ANTAGONISTS - The present invention relates to a compound of formula (I) | 07-30-2009 |
20090215847 | Tricyclic Angiotensin II Agonists - There is provided compounds of formula I, | 08-27-2009 |
20090215848 | Novel imidazolidIn-2-one derivatives as selective androgen receptor modulators (SARMS) - The present invention is directed to novel imidazolidin-2-one derivatives having a structure according to Formula I | 08-27-2009 |
20090221656 | Drug Combinations - A combination comprising at least two components selected from: | 09-03-2009 |
20090312382 | NOVEL IMIDAZOLIDINE DERIVATIVES - The invention is concerned with novel imidazolidine derivatives of formula (I) | 12-17-2009 |
20100105748 | METHODS AND COMPOSITIONS FOR TREATMENT OF DRUG ADDICTION - The present disclosure relates to methods of treating a stimulant addiction of a patient comprising administering to a patient in need a therapeutically effective dose of a selective dopamine β-hydroxylase inhibitor thereby decreasing stimulant reward, inducing aversion for the stimulant or preventing relapse in the patient. The disclosure further encompasses methods whereby a therapeutically effective dose of a selective dopamine β-hydroxylase inhibitor is determined by: characterizing the genetic profile of the patient with respect to the gene encoding dopamine β-hydroxylase, a polymorphism therein correlating to the level of endogenous dopamine β-hydroxylase activity in the patient before administering the therapeutic agent. | 04-29-2010 |
20100137389 | TOPICAL FORMULATION - The invention relates to composition and related therapeutic methods including at least one antihyperthyroid drug formulated for transdermal administration. Because the formulation is formulated for transdermal administration, the formulation is easier to administer than existing formulations which are administered orally to animals. Issues surrounding transdermal administration versus oral administration have also been resolved allowing the agent to remain stable during storage and retain a high level of efficacy. | 06-03-2010 |
20100137390 | 1,3-Dihydroimidazole-2-Thione Derivatives as Inhibitors of Dopamine-Beta-Hydroxylase - Compounds of formula I and a method for their preparation are described, where R | 06-03-2010 |
20100144813 | NOVEL 4-HETEROARYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND PHARMACEUTICAL/COSMETIC APPLICATIONS THEREOF - Novel 4-heteroarylimidazole-2-thione tyrosinase inhibiting compounds corresponding to the following general formula (I): | 06-10-2010 |
20100160401 | 4-PHENYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND TREATMENT OR PREVENTION OF PIGMENTARY DISORDERS THEREWITH - The tyrosinase inhibiting compounds of the following general formula | 06-24-2010 |
20100168195 | DERIVATIVES AND ANALOGS OF CHROMAN AS FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS - In its many embodiments, the present invention provides a novel class of chroman compounds of formula I as α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of prepaxing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions. | 07-01-2010 |
20100197750 | Preservation Of Ergothioneine - Compositions comprising ergothioneine and a trimethylamine absorber are provided. Also provided are methods for preventing, reducing or minimizing the fishy, amine odor, due to trimethylamine, that is associated with the processing and/or storage of a preparation containing ergothioneine, by combining with the ergothioneine, during processing or prior to storage, a trimethylamine absorber in an amount sufficient to prevent the detection of any trimethylamine odor by the human nose. A method is further provided for ameliorating the methylamine odor associated with an aqueous ergothioneine-containing preparation after it has developed a fishy trimethylamine odor. | 08-05-2010 |
20100216857 | METHOD OF TREATING MOTOR DISORDERS WITH 4-(1-(2,3-DIMETHYLPHENYL)ETHYL)-1H-IMIDAZOLE-2(3H)-THIONE - Disclosed herein is a method of treating motor disorders comprising administering to a subject in need of such treatment 4-(1-(2,3-dimethylphenyl)ethyl)-1H-imidazole-2(3H)-thione. | 08-26-2010 |
20100267792 | Topical Compositions Containing Desthiobiotin and its Derivatives and a Method of Treating Skin - Topical compositions and methods of use to treat symptoms of reduced skin elasticity are provided comprising desthiobiotin and certain desthiobiotin analogues. These compounds are effective in stimulating LOXL-1 activity and can thus increase elastin remodeling and improve appearance of fine lines, wrinkles, skin sagging and other symptoms of reduced elastin function. | 10-21-2010 |
20100286219 | 1, 3-Dihydroimidazoles for Treating Cardiovascular Disorders - A method comprising utilizing a compound of formula I: | 11-11-2010 |
20100298395 | UNSUBSTITUTED AND SUBSTITUTED 4-BENZYL-1,3-DIHYDRO-IMIDAZOLE-2-THIONES ACTING AS SPECIFIC OR SELECTIVE ALPHA2 ADRENERGIC AGONISTS AND METHODS FOR USING THE SAME - Compounds of Formula 1 | 11-25-2010 |
20110034525 | NONSEDATING ALPHA-2 AGONISTS - The present invention provides an α-2A/α-1A selective agonist that includes a compound represented by Structure 1 or a pharmaceutically acceptable salt, ester, amide, sterioisomer or racemic mixture thereof. The present invention further provides a pharmaceutical composition that contains a pharmaceutical carrier and a therapeutically effective amount of an α-2A/α-1A selective agonist that includes a compound represented by Structure 1 or a pharmaceutically acceptable salt, ester, amide, sterioisomer or racemic mixture thereof. | 02-10-2011 |
20110160262 | Method of treating retinal vein occlusion - A method for treating retinal vein occlusion involving administering to a patient a pharmacologically effective amount of a compound represented by the following formula (II) or a salt thereof: | 06-30-2011 |
20110178144 | THERAPEUTIC COMPOUNDS - Disclosed herein is a compound having a structure | 07-21-2011 |
20110269805 | METHOD OF TREATING SENSORIMOTOR DISORDERS WITH 4-(1-(2,3-DIMETHYLPHENYL)ETHYL)-1H-IMIDAZOLE-2(3H)-THIONE - Disclosed herein is a method of treating sensorimotor disorders comprising administering to a subject in need of such treatment 4-(1-(2,3-dimethylphenyl)ethyl)-1H-imidazole-2(3H)-thione. | 11-03-2011 |
20120136035 | 4-(1-(3-(HYDROXYMETHYL)-2-METHYLPHENYL)ETHYL)-1H-IMIDAZOLE-2(3H)-THIONE - Disclosed herein is 4-(1-(3-(hydroxymethyl)-2-methylphenyl)ethyl)-1H-imidazole-2(3H)-thione and methods of using the compound to treat chronic pain. | 05-31-2012 |
20120165380 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS - Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an α-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, acute, neuropathic and chronic. | 06-28-2012 |
20120190719 | METHODS OF TREATING MOTOR DISORDERS WITH ALPHA-2B ANDRENERGIC RECEPTOR AGONISTS - Disclosed herein is a method of treating compulsive disorders comprising administering to a subject in need of such treatment an alpha-2 receptor agonist. | 07-26-2012 |
20120196911 | UNSUBSTITUTED AND SUBSTITUTED 4-BENZYL-1,3-DIHYDRO-IMIDAZOLE-2-THIONES ACTING AS SPECIFIC OR SELECTIVE ALPHA2 ADRENERGIC AGONISTS AND METHODS FOR USING THE SAME - Compounds of Formula 1 | 08-02-2012 |
20120225917 | PEST CONTROL COMPOSITION - The present invention provides a pest control composition having an excellent controlling effect on pests, which comprises a combination of an ester compound represented by the formula (1): and a cyclic compound represented by the formula (2a) and/or a cyclic compound represented by the formula (2b). | 09-06-2012 |
20120238610 | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression - Treatment of autoimmune and/or inflammatory diseases associated with overexpression of Toll-like receptor 3 (TLR3) as well as Toll-like receptor 4 (TLR4) and/or TLR3/TLR4 signaling in nonimmune cells, monocytes, macrophages, and/or dendritic cells in association with related pathologies. The use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune and inflammatory diseases associated with TLR3 as well as TLR4 and/or TLR3/TLR4 cellular signaling in association with related pathologies is disclosed. Methods of treating a subject having a disease or condition associated with abnormal TLR-3 as well as TLR-4 and/or TLR3/TLR4 cellular signaling in association with related pathologies are also disclosed. The present disclosure also relates to the treatment of autoimmune-inflammatory pathologies and chemokine and cytokine-mediated diseases associated with TLR overexpression and signaling. The disclosure also relates to pharmaceutical formulations capable of inhibiting the IRF-3/Type 1 IFN/STAT/ISRE/IRF-1 pathway associated with Toll-like receptor overexpression or signaling. | 09-20-2012 |
20120270916 | TOPICAL FORMULATIONS FOR TREATING NEUROPATHY - Compositions for the topical or transdermal treatment of neuropathy. More particularly, transdermal or topical compositions including a combination of ingredients that provide a surprising degree of effective relief from the symptoms of peripheral neuropathy are described. | 10-25-2012 |
20120283303 | USE OF N-AMINOIMIDAZOLE CYTOPROTECTIVE COMPOUNDS FOR TREATING CELL DEATH AND/OR GSK-3 MEDIATED DISEASES - The present invention relates to the use of N-aminoimidazole or N-aminoimidazole thione derivatives as cytoprotective compounds in vitro and in vivo and for the treatment or prevention of cell death mediated disorders and/or GSK-3 mediated disorders or processes. | 11-08-2012 |
20130012558 | Use of Fungicides for the Treatment of Fish Mycoses - Process for the protection of fish and invertebrates and all their stages of development against or for the treatment of mycoses caused by fungi of the genera | 01-10-2013 |
20130023572 | PHARMACEUTICAL COMPOSITIONS COMPRISING 4-BROMO-N-(IMIDAZOLIDIN-2-YLIDENE)-1H-BENZIMIDAZOL-5-AMINE FOR TREATING SKIN DISEASES - The present invention relates to a method for treating skin diseases in a patient in need thereof which comprises of administering a pharmaceutical composition comprising a therapeutically effective amount of 4-bromo-N-(imidazolidin-2-ylidene)-1H-benzimidazol-5-amine or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. | 01-24-2013 |
20130023573 | ALPHA-2 ADRENERGIC MODULATORS FOR TREATING VISUAL DISORDERS MEDIATED BY CENTRAL VISUAL PROJECTIONS FROM THE EYE - The present invention relates to a method for treating visual disorders mediated by lateral geniculate nucleus, superior colliculus and the visual cortex by administering to a patient in need of such treatment, compounds acting at the alpha 2 adrenergic receptors. | 01-24-2013 |
20130035361 | USE OF ERGOTHIONEINE AS A PRESERVATIVE IN FOODS AND BEVERAGES - The invention relates to the novel use of ergothioneine and preferably, L ergothioneine, as a nutritional additive and preservative in foods, medicines, and/or beverages. According to the invention, the powerful antioxidant ergothioneine was found to be very stable over time in and to have no deleterious effects on taste or consistency of food and beverages even when stored, over a period of several years. In a preferred embodiment, ergothioneine may be used as a replacement for all or part of the antimicrobial/preservative sulfur dioxide or other sulfites traditionally used in the wine making process. | 02-07-2013 |
20130046003 | PHARMACEUTICAL COMPOSITIONS COMPRISING 4-BROMO-N-(IMIDAZOLIDIN-2-YLIDENE)-1H-BENZIMIDAZOL-5-AMINE FOR TREATING RETINAL DISEASES - The present invention relates to a method for treating retinal diseases and a method for retinal neuroprotection, in a patient in need thereof which comprises of administering a therapeutically effective amount of a pharmaceutical composition comprising a therapeutically effective amount of 4-bromo-N-(imidazolidin-2-ylidene)-1H-benzimidazol-5-amine or pharmaceutically acceptable salts thereof. | 02-21-2013 |
20130203827 | POLYMORPHISMS IN THE PDE3A GENE - Embodiments of the invention are directed to identifying or treating a patient that would benefit from phosphodiesterase inhibitor therapy. | 08-08-2013 |
20130210876 | ALPHA-2 ADRENERGIC AGONIST HAVING LONG DURATION OF INTRAOCULAR PRESSURE-LOWERING EFFECT - The present invention provides a method of lowering intraocular pressure which comprises administering a therapeutically effective amount of a pharmaceutical composition comprising 4-bromo-5-(2-imidazolin-2-ylamino)benzimidazole, or a salt thereof to the affected eye of a patient, as a single dose, wherein the affected eye maintains an intraocular pressure less than the baseline thereafter. | 08-15-2013 |
20130217739 | THERAPEUTIC COMPOUNDS - Disclosed herein is a compound having a structure | 08-22-2013 |
20130274303 | METHODS AND COMPOSITIONS FOR TREATMENT OF DRUG ADDICTION - The present disclosure relates to methods of treating a stimulant addiction of a patient comprising administering to a patient in need a therapeutically effective dose of a selective dopamine beta-hydroxylase inhibitor thereby decreasing stimulant reward, inducing aversion for the stimulant or preventing relapse in the patient. The disclosure further encompasses methods whereby a therapeutically effective dose of a selective dopamine beta-hydroxylase inhibitor is determined by: characterizing the genetic profile of the patient with respect to the gene encoding dopamine beta-hydroxylase, a polymorphism therein correlating to the level of endogenous dopamine beta-hydroxylase activity in the patient before administering the therapeutic agent. | 10-17-2013 |
20130345275 | 1,3-DIHYDROIMIDAZOLE-2-THIONE DERIVATIVES AS INHIBITORS OF DOPAMINE-BETA-HYDROXYLASE - Compounds of formula I and a method for their preparation are described: | 12-26-2013 |
20140080878 | HEPARANASE ACTIVITY INHIBITOR - A heparanase activity inhibitor comprising, as an active ingredient, a cyclic carboxamide derivative represented by formula (I): | 03-20-2014 |
20140235685 | PHARMACEUTICAL COMPOSITIONS COMPRISING 4-BROMO-N-(IMIDAZOLIDIN-2-YLIDENE)-1H-BENZIMIDAZOL-5-AMINE FOR TREATING SKIN DISEASES - The present invention relates to a method for treating skin diseases in a patient in need thereof which comprises of administering a pharmaceutical composition comprising a therapeutically effective amount of 4-bromo-N-(imidazolidin-2-ylidene)-1H-benzimidazol-5-amine or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. | 08-21-2014 |
20140315968 | Substituted 2-Imidazolidinones and 2-Imidazolones and Their Use in the Treatment of Cancer - Compounds of formula (I) wherein R | 10-23-2014 |
20150073027 | Preservation of Ergothioneine - Compositions comprising ergothioneine and a trimethylamine absorber are provided. Also provided are methods for preventing, reducing or minimizing the fishy, amine odor, due to trimethylamine, that is associated with the processing and/or storage of a preparation containing ergothioneine, by combining with the ergothioneine, during processing or prior to storage, a trimethylamine absorber in an amount sufficient to prevent the detection of any trimethylamine odor by the human nose. A method is further provided for ameliorating the methylamine odor associated with an aqueous ergothioneine-containing preparation after it has developed a fishy trimethylamine odor. | 03-12-2015 |
20150133516 | Methods and Compositions for Treating ADHD - The present invention provides compositions and methods of using α2 adrenergic receptor agonists as treatments for ADHD. The α2 adrenergic receptor agonist for use with these methods is a benzimidazole derivative, and may be specifically N-(4,5-Dihydro-1H-imidazol-2-yl)-7-cyano-4-methyl-1H-benzimidazol-5-amine acetate. Formulations and routes of administration are also described. | 05-14-2015 |
20160067221 | USE OF ERGOTHIONEINE FOR INDUCING ACTIVITY OF NRF2 IN CELL - A method for inducing an activity of an Nrf2 in a cell is disclosed. The method includes administering to the cell a therapeutically effective amount of an ergothioneine that induces an expression of the Nrf2, wherein the cell is a normal cell or a damaged cell resulting from an exposure to an ultraviolet radiation (UVR). | 03-10-2016 |